Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc (ACOG) is a clinical-stage biopharmaceutical company advancing novel treatments for Alzheimer's disease and cognitive impairments linked to mild traumatic brain injury. This page provides investors and medical professionals with essential updates on therapeutic developments, regulatory milestones, and strategic initiatives in neurodegenerative care.
Find timely updates on clinical trial progress, FDA communications, and research partnerships directly from the company. Our curated news collection simplifies tracking of ACOG's pipeline candidates, including therapies targeting unmet needs in neurological disorders.
Key updates include developments in Phase 2/3 clinical studies, intellectual property expansions, and manufacturing scale-up announcements. All content is sourced from official releases to ensure compliance with financial disclosure standards.
Bookmark this page for streamlined access to verified ACOG developments. Check back regularly for critical updates impacting the company's position in the $1.3 trillion global neurology market.
Alpha Cognition (NASDAQ:ACOG) reported significant progress in Q2 2025, marking its first full quarter of ZUNVEYL® commercialization. The company achieved ~$2M YTD net product revenue, with the drug being ordered in over 300 long-term care facilities and maintaining a 65% repeat order rate.
Key developments include securing a national Medicare Part D contract without prior authorization requirements, and China Medical System's New Drug Application (NDA) acceptance by NMPA. Additionally, the company completed a Department of Defense-funded Bomb Blast study demonstrating ALPHA-1062's efficacy in reducing neuroinflammation and toxic Tau proteins in mild traumatic brain injury (mTBI).
Alpha Cognition (NASDAQ:ACOG) reported Q2 2025 financial results and operational updates, highlighting the successful launch of ZUNVEYL with $2 million in net product revenues year-to-date, including $1.6 million in Q2. The company's sales team has engaged with over 3,700 healthcare professionals and generated prescriptions in more than 300 nursing homes.
The company secured its first national Medicare Part D contract without prior authorization requirements. Additionally, ACOG completed a pre-clinical Bomb Blast study for ALPHA-1062 with the U.S. Department of Defense, showing reduced neuroinflammation and neuropathology associated with blast trauma.
Financial position remains strong with $39.4 million in cash as of June 30, 2025, providing an estimated two-year runway at current utilization rates. The company reported a Q2 net loss of $10.5 million, including a $5.2 million non-cash warrant liability adjustment.
Alpha Cognition (Nasdaq: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, will release its Q2 2025 financial results on August 14, 2025 after market close.
The company will host a conference call to discuss the results, with management providing a detailed review of financial performance and operational updates. Investors can access the call through various channels, including telephone dial-in and a live audio webcast.
Alpha Cognition (Nasdaq: ACOG) announced that its partner China Medical System Holdings Limited (CMS) has received acceptance of the New Drug Application (NDA) for ZUNVEYL® (Benzgalantamine) by China's National Medical Products Administration (NMPA) for review. The application is for treating mild-to-moderate Alzheimer's dementia.
The company stands to receive regulatory and sales milestones, plus royalties upon ZUNVEYL's approval in China and other Asian territories. According to Lancet Public Health, there are approximately 7.93 million patients with mild-to-moderate Alzheimer's dementia in China, with numbers expected to rise due to aging population trends.
Alpha Cognition (Nasdaq: ACOG) announced it will present new clinical data for its Alzheimer's treatment ZUNVEYL® at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada.
The company will present three poster presentations focusing on ZUNVEYL's bioequivalence to galantamine hydrobromide in different conditions and its dose proportionality. The presentations will showcase data from studies examining doses ranging from 5 to 15 milligrams under various conditions, including fed and fasting states.
Alpha Cognition (Nasdaq: ACOG) announced positive preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), particularly focusing on blast trauma injuries relevant to military personnel. The study, supported by the US Department of Defense and conducted with VA investigators, demonstrated significant therapeutic potential.
The research revealed that ALPHA-1062 reduced three toxic forms of brain protein Tau: pTau 217 (linked to long-term cognitive decline risk), pTau-S202/T205 (present in early-stage Alzheimer's pathology), and pTau 231 (elevated in early Alzheimer's and TBI). Additionally, high-dose ALPHA-1062 showed positive effects by reducing neuroinflammation markers and increasing nerve growth factor receptor expression.
The company's next steps include completing formulation of ALPHA-1062 for sublingual administration and conducting a bridging pharmacokinetic study comparing it to ZUNVEYL® and an existing intranasal formulation.
Alpha Cognition (NASDAQ: ACOG) has successfully launched its product ZUNVEYL(R) (benzgalantamine) in the U.S. long-term care (LTC) market on March 17, 2025. The launch has shown positive early results with strong clinician and patient feedback, successful patient outcomes, and robust ordering momentum. The company secured Medicare reimbursement post-launch, enhancing patient access in LTC settings. Additionally, ACOG obtained a new composition of matter patent for the tablet formulation of benzgalantamine in the U.S.
Financial highlights include ZUNVEYL net product revenues of $0.35M and licensing revenue of $2.6M. Management confirmed that all launch objectives remain on track and within budget, with commercial execution proceeding according to plan.
Alpha Cognition (NASDAQ: ACOG) reported its Q1 2025 financial results, highlighting the successful launch of ZUNVEYL (benzgalantamine) in the US long-term care market on March 17, 2025. The company secured $2.6M in licensing revenues from its partnership with CMS Pharma and reported initial ZUNVEYL product revenues of $347,000.
The company's net loss decreased to $2.0M from $5.0M in the same period last year. Cash position stands at $45.5M as of March 31, 2025, providing an estimated two-year runway. The company strengthened its intellectual property portfolio with a new composition patent extending ZUNVEYL's US protection through 2044.
Alpha Cognition (NASDAQ: ACOG), a biopharmaceutical company focused on neurodegenerative disease treatments, will release its Q1 2025 financial results on May 15, 2025 after market close. The company will host a conference call to discuss the results and provide an operating overview on the same day at 4:30 PM ET.
Investors can participate in the conference call using the dial-in numbers 1-877-407-9039 or 1-201-689-8470. A Call me™ feature is available to avoid operator wait times, and participants can access the live audio webcast through the provided links. A replay will be available via webcast or by calling 1-844-512-2921 or 1-412-317-6671 with Access ID: 13753070.
Alpha Cognition (NASDAQ: ACOG) has announced its upcoming participation in the D. Boral Capital Inaugural Global Conference. The event is scheduled for May 14, 2025, at The Plaza Hotel in New York City.
Company CEO Michael McFadden will be available for one-on-one meetings throughout the conference day from 9:00 A.M. to 3:00 P.M. (ET). Interested parties who wish to schedule meetings with the management team can make arrangements by contacting John Perez at jperez@dboralcapital.com.
This conference participation represents an opportunity for investors and stakeholders to engage directly with Alpha Cognition's leadership and learn more about the company's developments and strategies.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
